A Phase 2 non-randomized, open-label, multi-cohort, multi-center study assessing the clinical benefit of SAR444245 (THOR-707) combined with other anticancer therapies for the treatment of participants with head and neck squamous cell carcinoma (HNSCC)

Study category: Cancer

Is this Study for You?

Let's Get Started!




INCLUSION: - Histologically or cytologically confirmed diagnosis of R/M HNSCC that is considered not amenable to further therapy with curative intent. The eligible primary tumor locations are oropharynx, oral cavity, hypopharynx, and larynx (nasopharynx is excluded). - Known HPV p16 status for oropharyngeal cancer. EXCLUSION: - Has received prior IL2-based anti-cancer treatment.

Type of Study



University of Colorado Hospital

Principal Investigator
Antonio Jimeno,  MD, PhD

Antonio Jimeno, MD, PhD

Study ID

Protocol Number: 21-4146

More information available at ClinicalTrials.gov: NCT05061420


Is this Study for You?

Let's Get Started!

Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers